Immuron achieves record half yearly Travelan® sales

Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has reported record half yearly sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®, with total sales reaching A$2,355,580 in H1, FY24. This marks a significant increase of $1,771,932 compared to H1, FY23 sales and a 51% increase over pre-pandemic period H1, FY20 sales. Australian sales of Travelan® increased by 132% compared to H1, FY23, while USA sales saw a slight decrease of 6% compared to the pre-pandemic peak period H1, FY20. Despite this, the Amazon launch in the USA is progressing well, with sales already ahead of budget. The company anticipates strong sales growth closer to the peak spring/summer travel period.

Positive

• Record half yearly sales of Travelan® at $2,334,969
• Total sales of A$2,355,580 in H1, FY24
• 51% higher than pre-pandemic period H1, FY20 sales
• Australian sales of Travelan® increased by 132%
• Amazon launch in the USA progressing well
• Strong anticipated sales growth closer to peak travel period

Negative

• USA sales of Travelan® decreased by 6% compared to the pre-pandemic peak period H1, FY20

Highlights:

• Record half yearly Travelan^® sales of $2,334,969
• Total sales of A$2,355,580 in H1, FY24
  • $1,771,932 increase on H1, FY23 sales
  • 51% higher than pre-pandemic period H1, FY20 sales

MELBOURNE, Australia, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record half yearly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan^®.

Australia

Sales of Travelan^® increased to AUD $1,853,048 in H1, FY24, compared to AUD $260,205 in H1, FY23. Sales increased by $1,054,164 (132%) on the pre-pandemic peak period (H1, FY20).

This increase partially reflects 3 months (May, June, July) of backorders accrued while awaiting GMP Clearance from the TGA.

Australian Bureau of Statistics: short term resident returns in October 2023 were 47% higher than October 2022 and approaching pre-pandemic levels (93% of October 2019)¹.

USA

Sales of Travelan^® increased to AUD $481,920 in H1, FY24, compared to AUD $295,411 in H1, FY23. Sales were lower by $31,633 (-6%) on the pre-pandemic peak period (H1, FY20).

International Trade Administration Total U.S. citizen international visitor departures from the United States in September 2023 were 17% higher than in September 2022. ²

Immuron’s target departure markets ³, July - September 2023 departures were 1% higher than the pre-pandemic period July - September 2019. ²

Immuron previously reported (July 5, 2023) that it had shipped inventory to Amazon for launch in USA. The Amazon launch continues to progress well with sales ahead of budget. We are now entering the low travel season in USA. Immuron anticipates sales to grow strongly closer to the peak spring / summer travel period.

1. https://www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release
2. https://www.trade.gov/sites/default/files/2023-12/US-Outbound-to-World-Regions.xlsx
3. Caribbean, Asia, South America, Central America, Africa, Mexico
   

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT: Steven Lydeamore Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information visit: http://www.immuron.com

FAQ

What are the ticker symbols for Immuron Limited?

The ticker symbols for Immuron Limited are ASX: IMC and NASDAQ: IMRN.

What were the total sales of Travelan® in H1, FY24?

The total sales of Travelan® in H1, FY24 were A$2,355,580.

How much did Australian sales of Travelan® increase by in H1, FY24?

Australian sales of Travelan® increased by 132% in H1, FY24 compared to H1, FY23.

What was the percentage change in USA sales of Travelan® compared to the pre-pandemic peak period?

USA sales of Travelan® decreased by 6% compared to the pre-pandemic peak period H1, FY20.

What is the status of the Amazon launch in the USA?

The Amazon launch in the USA is progressing well, with sales ahead of budget.

What does Immuron anticipate in terms of sales growth?

Immuron anticipates strong sales growth closer to the peak spring/summer travel period.